Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas

References

• Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008;58:32–53. PubMed PMID: 18096865
   PubMed Web of Science ®Google Scholar
• Parfenov M, Pedamallu CS, Gehlenborg N, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111:15544–15549. PubMed PMID: 25313082. PubMed Central PMCID: 4217452
   PubMed Web of Science ®Google Scholar
• Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 2009;1:6. PubMed PMID: 19284526. PubMed Central PMCID: 2660327
   PubMedGoogle Scholar
• Wen Y, Grandis JR. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2015;20:313–329. PubMed PMID: 25826749. PubMed Central PMCID: 5678969
   PubMed Web of Science ®Google Scholar
• Kumar B, Cordell KG, D’Silva N, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134:363–369. PubMed PMID: 18427001. PubMed Central PMCID: 3342859
   PubMedGoogle Scholar
• Bradford CR, Kumar B, Bellile E, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014;124:179–187. PubMed PMID: 23775802. PubMed Central PMCID: 4123871
   PubMed Web of Science ®Google Scholar
• Deng Z, Hasegawa M, Yamashita Y, et al. Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci. 2012;103:2127–2134. PubMed PMID: 22937809
   PubMed Web of Science ®Google Scholar
• Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60. PubMed PMID: 21193867
   PubMed Web of Science ®Google Scholar
• Bhola NE, Thomas SM, Freilino M, et al. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res. 2011;17:4996–5004. PubMed PMID: 21653688. PubMed Central PMCID: 3149755
   PubMed Web of Science ®Google Scholar
• Bhola NE, Freilino ML, Joyce SC, et al. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012;11:1236–1246. PubMed PMID: 22491800. PubMed Central PMCID: 3413198
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene. 2007;26:5762–5771. PubMed PMID: 17384686.
   PubMed Web of Science ®Google Scholar
• Misawa K, Ueda Y, Kanazawa T, et al. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res. 2008;14:7604–7613. PubMed PMID: 19047085. PubMed Central PMCID: 3189853.
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Kommareddi PK, Iwashita T, et al. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res. 2009;15:2222–2230. PubMed PMID: 19276245. PubMed Central PMCID: 3315370.
   PubMed Web of Science ®Google Scholar
• Misawa K, Kanazawa T, Misawa Y, et al. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. J Cancer Res Clin Oncol. 2013;139:879–889. PubMed PMID: 23420374
   PubMed Web of Science ®Google Scholar
• Misawa K, Kanazawa T, Misawa Y, et al. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Transl Oncol. 2013;6:338–346. PubMed PMID: 23730414. PubMed Central PMCID: 3660803.
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Misawa K, Misawa Y, et al. Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC. Mol Med Rep. 2014;10:1289–1294. PubMed PMID: 25017118
   PubMed Web of Science ®Google Scholar
• Misawa Y, Misawa K, Kanazawa T, et al. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer. 2014;120:205–213. PubMed PMID: 24122450.
   PubMed Web of Science ®Google Scholar
• Uehara T, Kanazawa T, Mizukami H, et al. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci. 2014;105:72–80. PubMed PMID: 24168112. PubMed Central PMCID: 4317884
   PubMed Web of Science ®Google Scholar
• Misawa K, Misawa Y, Kondo H, et al. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. PLOS ONE. 2015;10:e0118588. PubMed PMID: 25734919. PubMed Central PMCID: 4348545
   PubMed Web of Science ®Google Scholar
• Misawa K, Misawa Y, Kanazawa T, et al. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis. 2016;33:187–195. PubMed PMID: 26572146
   PubMed Web of Science ®Google Scholar
• Misawa K, Mochizuki D, Imai A, et al. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Oncotarget. 2016;7:26087–26098. PubMed PMID: 27027429. PubMed Central PMCID: 5041966
   PubMedGoogle Scholar
• Misawa K, Imai A, Mochizuki D, et al. Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis. Oncotarget. 2017;8:76318–76328. PubMed PMID: 29100314. PubMed Central PMCID: 5652708
   PubMedGoogle Scholar
• Misawa K, Mochizuki D, Endo S, et al. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: potential utility as biomarkers for prognosis. Mol Carcinog. 2017;56:1107–1116. PubMed PMID: 27685843
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Misawa K, Fukushima H, et al. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: potential utility as biomarkers for prognosis. Oncol Lett. 2018;15:9043–9050. PubMed PMID: 29805635. PubMed Central PMCID: 5958682
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Seki N, Shimizu S, et al. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer. 2009;48:132–142. PubMed PMID: 18973137
   PubMed Web of Science ®Google Scholar
• Habert-Ortoli E, Amiranoff B, Loquet I, et al. Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci U S A. 1994;91:9780–9783. PubMed PMID: 7524088. PubMed Central PMCID: 44900
   PubMed Web of Science ®Google Scholar
• Wang S, Hashemi T, Fried S, et al. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry. 1998;37:6711–6717. PubMed PMID: 9578554
   PubMed Web of Science ®Google Scholar
• Smith KE, Walker MW, Artymyshyn R, et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem. 1998;273:23321–23326. PubMed PMID: 9722565
   PubMed Web of Science ®Google Scholar
• Takebayashi S, Ogawa T, Jung KY, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res. 2000;60:3397–3403. PubMed PMID: 10910046
   PubMed Web of Science ®Google Scholar
• Henson BS, Neubig RR, Jang I, et al. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem. 2005;280:22564–22571. PubMed PMID: 15767248
   PubMed Web of Science ®Google Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14:342–346. PubMed PMID: 18223206
   PubMed Web of Science ®Google Scholar
• Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem. 1998;273:1839–1842. PubMed PMID: 9442012
   PubMed Web of Science ®Google Scholar
• Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A. 1997;94:448–452. PubMed PMID: 9012803. PubMed Central PMCID: 19532
   PubMed Web of Science ®Google Scholar
• Dixon BS, Evanoff D, Fang WB, et al. Bradykinin B1 receptor blocks PDGF-induced mitogenesis by prolonging ERK activation and increasing p27Kip1. Am J Physiol Cell Physiol. 2002;283:C193–203. PubMed PMID: 12055088
   PubMed Web of Science ®Google Scholar
• Lahlou H, Saint-Laurent N, Esteve JP, et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem. 2003;278:39356–39371. PubMed PMID: 12878607
   PubMed Web of Science ®Google Scholar
• Woods D, Parry D, Cherwinski H, et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997;17:5598–5611. PubMed PMID: 9271435. PubMed Central PMCID: 232408
   PubMed Web of Science ®Google Scholar
• Gendron L, Oligny JF, Payet MD, et al. Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem. 2003;278:3606–3614. PubMed PMID: 12464615
   PubMed Web of Science ®Google Scholar
• Kranenburg O, Moolenaar WH. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene. 2001;20:1540–1546. PubMed PMID: 11313900
   PubMed Web of Science ®Google Scholar
• Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–3385. PubMed PMID: 9270000
   PubMed Web of Science ®Google Scholar
• Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002;62:3819–3825. PubMed PMID: 12097295
   PubMed Web of Science ®Google Scholar
• Massarelli E, Brown E, Tran NK, et al. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005;103:952–959. PubMed PMID: 15666322
   PubMed Web of Science ®Google Scholar
• Hoffmann MJ, Florl AR, Seifert HH, et al. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer. 2005;114:406–413. PubMed PMID: 15551363
   PubMed Web of Science ®Google Scholar
• Kong S, Amos CI, Luthra R, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res. 2000;60:249–252. PubMed PMID: 10667569
   PubMed Web of Science ®Google Scholar
• Akervall J, Bockmuhl U, Petersen I, et al. The gene ratios c-MYC: cyclin-dependentkinase (CDK)N2A and CCND1: CDKN2Acorrelate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2003;9(5):1750–1755. PubMed PMID: 12738730
   PubMed Web of Science ®Google Scholar
• Doufekas K, Hadwin R, Kandimalla R, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer. 2013;23:1050–1055. PubMed PMID: 23727823
   PubMed Web of Science ®Google Scholar
• Jee KJ, Persson M, Heikinheimo K, et al. Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Modern Pathol. 2013;26:213–222. PubMed PMID: 23018873
   PubMed Web of Science ®Google Scholar
• Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 2002;3:755–763. PubMed PMID: 12473517
   PubMed Web of Science ®Google Scholar
• Wittau N, Grosse R, Kalkbrenner F, et al. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene. 2000;19:4199–4209. PubMed PMID: 10980593
   PubMed Web of Science ®Google Scholar
• Tofighi R, Joseph B, Xia S, et al. Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci U S A. 2008;105:2717–2722. PubMed PMID: 18272487. PubMed Central PMCID: 2268202
   PubMed Web of Science ®Google Scholar
• Berger A, Lang R, Moritz K, et al. Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology. 2004;145:500–507. PubMed PMID: 14592962
   PubMed Web of Science ®Google Scholar
• Banerjee R, Henson BS, Russo N, et al. Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma. Cell Signal. 2011;23:1110–1118. PubMed PMID: 21345369. PubMed Central PMCID: 3090707
   PubMed Web of Science ®Google Scholar
• Banerjee R, Van Tubergen EA, Scanlon CS, et al. The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer. Mol Cancer Ther. 2014;13:1323–1333. PubMed PMID: 24568968. PubMed Central PMCID: 4023835
   PubMed Web of Science ®Google Scholar
• Pin JP, Neubig R, Bouvier M, et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev. 2007;59:5–13. PubMed PMID: 17329545
   PubMed Web of Science ®Google Scholar
• Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther. 2007;115:177–207. PubMed PMID: 17604107
   PubMed Web of Science ®Google Scholar
• Smith KE, Forray C, Walker MW, et al. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem. 1997;272:24612–24616. PubMed PMID: 9305929
   PubMed Web of Science ®Google Scholar
• Wang S, Clemmons A, Strader C, et al. Evidence for hydrophobic interaction between galanin and the GalR1 galanin receptor and GalR1-mediated ligand internalization: fluorescent probing with a fluorescein-galanin. Biochemistry. 1998;37:9528–9535. PubMed PMID: 9649336
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Misawa K, Carey TE. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets. 2010;14:289–302. PubMed PMID: 20148716
   PubMed Web of Science ®Google Scholar
• Fathi Z, Battaglino PM, Iben LG, et al. Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res. 1998;58:156–169. PubMed PMID: 9685625
   PubMedGoogle Scholar
• Wang S, Hashemi T, He C, et al. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol. 1997;52:337–343. PubMed PMID: 9281594
   PubMed Web of Science ®Google Scholar
• Hobson SA, Vanderplank PA, Pope RJ, et al. Galanin stimulates neurite outgrowth from sensory neurons by inhibition of Cdc42 and Rho GTPases and activation of cofilin. J Neurochem. 2013;127:199–208. PubMed PMID: 23895321. PubMed Central PMCID: 3935412
   PubMed Web of Science ®Google Scholar
• Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLOS ONE. 2008;3:e2079. PubMed PMID: 18446232. PubMed Central PMCID: 2323612
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang HY, Ma ZZ, et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res. 2003;13:319–333. PubMed PMID: 14672555
   PubMed Web of Science ®Google Scholar
• Kim JC, Lee HC, Cho DH, et al. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol. 2011;137:1571–1580. PubMed PMID: 21850381
   PubMed Web of Science ®Google Scholar
• Huang WY, Hsu SD, Huang HY, et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 2015;43:D856–D861. PubMed PMID: 25398901. PubMed Central PMCID: 4383953
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. PubMed PMID: 23550210. PubMed Central PMCID: 4160307
   PubMed Web of Science ®Google Scholar
• Tan HK, Saulnier P, Auperin A, et al. Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas. Br J Cancer. 2008;99:357–363. PubMed PMID: 18594522. PubMed Central PMCID: 2480979
   PubMed Web of Science ®Google Scholar
• Supic G, Kozomara R, Jovic N, et al. Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas. Oral Oncol. 2011;47:702–708. PubMed PMID: 21697000
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nelson HH, Peters E, et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 2002;21:4231–4236. PubMed PMID: 12082610
   PubMed Web of Science ®Google Scholar
• Pierini S, Jordanov SH, Mitkova AV, et al. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients. Head Neck. 2014;36:1103–1108. PubMed PMID: 23804521
   PubMed Web of Science ®Google Scholar
• Paluszczak J, Misiak P, Wierzbicka M, et al. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol. 2011;47:104–107. PubMed PMID: 21147548
   PubMed Web of Science ®Google Scholar
• Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res. 2002;8:3164–3171. PubMed PMID: 12374684
   PubMed Web of Science ®Google Scholar
• Warta R, Herold-Mende C, Chaisaingmongkol J, et al. Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. Int J Cancer. 2014;135:2727–2734. PubMed PMID: 24740185
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Posner MR, McClean MD, et al. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer. 2008;113:1566–1571. PubMed PMID: 18711702. PubMed Central PMCID: 3645304
   PubMed Web of Science ®Google Scholar
• Roh JL, Wang XV, Manola J, et al. Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study. Clin Cancer Res. 2013;19:2528–2540. PubMed PMID: 23444219. PubMed Central PMCID: 3642232
   PubMed Web of Science ®Google Scholar
• De Schutter H, Geeraerts H, Verbeken E, et al. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep. 2009;21:507–513. PubMed PMID: 19148529
   PubMed Web of Science ®Google Scholar
• Chen B, Chen J, House MG, et al. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res. 2012;10:305–315. PubMed PMID: 22246235
   PubMed Web of Science ®Google Scholar
• Ogawa T, Liggett TE, Melnikov AA, et al. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle. 2012;11:1656–1663. PubMed PMID: 22487682. PubMed Central PMCID: 3341232
   PubMed Web of Science ®Google Scholar
• Kostareli E, Holzinger D, Hess J. New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Oncol. 2012;2:36. PubMed PMID: 22655271. PubMed Central PMCID: 3356125
   PubMedGoogle Scholar
• van Kempen PM, Noorlag R, Braunius WW, et al. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics. 2014;9:194–203. PubMed PMID: 24169583. PubMed Central PMCID: 3962529
   PubMed Web of Science ®Google Scholar
• Worsham MJ, Chen KM, Ghanem T, et al. Epigenetic modulation of signal transduction pathways in HPV-associated HNSCC. Otolaryngol Head Neck Surg. 2013;149:409–416. PubMed PMID: 23736812. PubMed Central PMCID: 3935612
   PubMed Web of Science ®Google Scholar
• Gubanova E, Brown B, Ivanov SV, et al. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res. 2012;18:1257–1267. PubMed PMID: 22247495. PubMed Central PMCID: 4010255
   PubMed Web of Science ®Google Scholar
• Lleras RA, Smith RV, Adrien LR, et al. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res. 2013;19:5444–5455. PubMed PMID: 23894057. PubMed Central PMCID: 3892374
   PubMed Web of Science ®Google Scholar
• Lechner M, Fenton T, West J, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 2013;5:15. PubMed PMID: 23419152. PubMed Central PMCID: 3706778
   PubMed Web of Science ®Google Scholar
• Colacino JA, Dolinoy DC, Duffy SA, et al. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLOS ONE. 2013;8:e54742. PubMed PMID: 23358896. PubMed Central PMCID: 3554647
   PubMed Web of Science ®Google Scholar
• Koffler J, Sharma S, Hess J. Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. Mol Cell Oncol. 2014;1:e954827. PubMed PMID: 27308324. PubMed Central PMCID: 4905189
   PubMedGoogle Scholar
• Fertig EJ, Markovic A, Danilova LV, et al. Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLOS ONE. 2013;8:e78127. PubMed PMID: 24223768. PubMed Central PMCID: 3817178
   PubMed Web of Science ®Google Scholar
• Kostareli E, Holzinger D, Bogatyrova O, et al. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest. 2013;123:2488–2501. PubMed PMID: 23635773. PubMed Central PMCID: 3668826
   PubMed Web of Science ®Google Scholar
• Lindsay C, Seikaly H, Biron VL. Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets. J Otolaryngol Head Neck Surg. 2017;46:9. PubMed PMID: 28143553. PubMed Central PMCID: 5282807
   PubMed Web of Science ®Google Scholar
• Ceccacci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer. 2016;114:605–611. PubMed PMID: 26908329. PubMed Central PMCID: 4800301
   PubMed Web of Science ®Google Scholar
• Gasche JA, Goel A. Epigenetic mechanisms in oral carcinogenesis. Future Oncol. 2012;8:1407–1425. PubMed PMID: 23148615. PubMed Central PMCID: 3569850
   PubMed Web of Science ®Google Scholar
• Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13:1634–1637. PubMed PMID: 17363514
   PubMed Web of Science ®Google Scholar
• Issa JP. Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res (Phila). 2008;1:219–222. PubMed PMID: 19138962
   PubMed Web of Science ®Google Scholar
• McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res. 2002;62:4757–4766. PubMed PMID: 12183435
   PubMed Web of Science ®Google Scholar
• Tang XH, Albert M, Scognamiglio T, et al. A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Cancer Prev Res (Phila). 2009;2:1100–1110. PubMed PMID: 19952362. PubMed Central PMCID: 2877493
   PubMed Web of Science ®Google Scholar
• Viet CT, Dang D, Achdjian S, et al. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLOS ONE. 2014;9(11):e112880. PubMed PMID: 25391133. PubMed Central PMCID: 4229295
   PubMed Web of Science ®Google Scholar
• Ferreira MB, Lima JP, Cohen EE. Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012;21:281–295. PubMed PMID: 22239178
   PubMed Web of Science ®Google Scholar
• Smits KM, Melotte V, Niessen HE, et al. Epigenetics in radiotherapy: where are we heading? Radiother Oncol. 2014;111:168–177. PubMed PMID: 24861629
   PubMed Web of Science ®Google Scholar